Predicting the structure of these compounds has been the missing link in developing drugs that can eradicate these devastating diseases once and for all.
Chemical Fingerprints will be both licensing out our revolutionary software to fellow drug makers as well as working parallel with them to create anti-amyloid and anti-neurodegenerative drugs.
This is a real chance to save millions of lives around the world who suffer from neurodegenerative diseases. We are the only provider of a software anything close to the power of NeuroteX, and with it, Chemical Fingerprints is going to change the world.
Traditional methods of anti-amyloid and anti-neurodegenerative drug discovery involves developing drug molecules without knowing the structure of the beta amyloid. This has always been the critical crux of the problem.
Without knowing the structure, drug developers can’t target exactly where the amyloid molecules are binding. If they knew the structure, they could target the binding site, and develop drugs to increase effectiveness for that binding site type and specifically target the site of the bind.
Now they can, with NeuroteX.
Using NeuroteX software, researchers will significantly reduce the time and cost to develop new therapeutics. Our technology enables the biotechnology industry to rapidly discover patentable vaccines that can neutralize the amyloid fibrils and protein oligomers that lead to neurodegenerative diseases.
The platform consists of a standalone software designed specifically to address every step of the amyloid conformation in the drug development path, from data visualization to structural analysis and protein engineering.
The exact science is quite complex, but the simple version goes like this: neurodegenerative diseases like Alzheimer’s and Parkinson’s are caused by amyloid fibrils in the brain that should be soluble, but have become insoluble. NeuroteX will break down these structures so researchers can see exactly where that insoluble bind is — this has never been possible before.
Because they can now target a specific site, the process of testing specific drugs and treatments becomes much quicker and more efficient. The overall goal of these researchers is to discover the specific treatment that stimulates the activity of the brain’s immune cells which can then kill the mutated amyloid fibrils.
NeuroteX isn’t the cure for Alzheimer’s, Parkinson’s, and other neurological disorders, but it is the tool that will discover the cure.
So, when can we expect NeuroteX to be in use?
Timeline
Over the next 2.5 years, we will go through 4 phases of development:
Phase I: Software development
Phase II: Cell line development for drug testing
Phase III: Drug development for Alzheimer’s and other neurodegenerative diseases
Phase IV: Small molecules as adjuvants for vaccine development
We are currently in the processes of patenting our software. Our goal is to give scientists the tools to efficiently and seamlessly test and discover their own anti-neurodegenerative drugs. We will be using our patent protected software to develop our own drug molecules as well. Once we prove the drug targets this specific site of binding, we can patent all of them.
To build the structure of a genetic fiber is a very hard task. For the past 5 years, we have been studying all neurological disorders and all structures. We’re now bringing it all together in one software package. Very few scientists have this knowledge and even fewer can apply it in a software. Chemical Fingerprints has cracked the code, now we just need help building it.
Next Steps: We need to hire two software programmers to develop the software and two research scientists for drug and cell culture development. With these hires, we can launch a beta of our software in 14-16 months.
Management
Dr. Nataraj Sekhar Pagadala (Founder/CEO)
Experience
Education
Employment
Dr. Malla, R.V. Sudarshan, Ph.D
Employment
Education
Research
Dr. Paramahamsa Maturu
Baskar Ramdas, Ph.D